相关实验视频

Updated: Jul 6, 2026

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

结构优化衍生HDAC6异形选择性抑制剂的设计,合成和评估

Chen Chen¹, Xiaochun Ma², Yichao Wan³

¹Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., Ltd., Jinan,250100, PR China.

Bioorganic chemistry

|May 10, 2025

概括

研究人员开发了一种强效和选择性的HDAC6抑制剂HDSI-18,通过抑制癌细胞增殖而不会引起毒性,显示出抗癌化疗的前景.

科学领域:

生物化学生化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

基斯脱乙酶6 (HDAC6) 是一个经过验证的抗癌点,因为它在细胞增殖中的作用.
准HDAC6为癌症治疗提供了一个潜在的治疗策略.

研究的目的:

设计和合成新的HDAC6选择性抑制剂.
评估这些抑制剂的抗癌潜力,重点关注有效性和选择性.

主要方法:

基于结构的药物设计和三轮优化.
在体外测试以确定抑制活性 (IC50) 和异型选择性.
在体外和体内研究,以评估抗增殖效应,亡诱导和药物可用性.

主要成果:

HDSI-18显示出强大的HDAC6抑制 (IC50=1.6nM) 具有特殊的选择性 (>975倍).
HDSI-18表现出显著的抗增殖活性,通过caspase-3激活和线粒体去极化诱导了亡.
在体外和体内观察到有希望的HDSI-18.18药物可用性概况.

结论:

HDSI-18是一种强效和选择性的HDAC6抑制剂,具有显著的抗癌特性.
这项研究为开发新的HDAC6向癌症疗法提供了合理的设计策略.

关键词:

这是一种抗瘤药物.细胞灭亡 (apoptosis) 是一种死亡的过程.在 HDAC6 中.异形选择性抑制剂异形选择性抑制剂结构优化结构优化

更多相关视频

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...